Marksans Pharma Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Marksans Pharma Share Price

249.832.92 (1.18%)

Closed
As On: 11 Jun, 2026, 03:54 PM IST
As On: 11 Jun, 2026, 03:58 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	245.40
High	257.97
Low	242.88
Prev Close	246.92
Volume	36,79,048
VWAP(₹)	253.33

Key Metrics

PE Ratio(x)	27.09
EPS - TTM(₹)	9.22
MCap(₹ Cr.)	11,336.34
MCap Rank	42
PB Ratio(x)	3.67
Div Yield(%)	0.36
Face Value(₹)	1.00
52W High(₹)	270.70
52W Low(₹)	155.00
MCap/Sales	2.41
Beta(1 Month)	2.64
BV/Share(₹)	67.36

Marksans Pharma share price insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 14.26% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Stock Screener Highlights
Marksans Pharma is a part of Mid-cap Growth Stocks Screener
Marksans Pharma Share Price Update
Marksans Pharma Ltd. share price moved up by 1.18% from its previous close of Rs 246.92. Marksans Pharma Ltd. stock last traded price is 249.83
Share Price Value
Today/Current/Last 249.83250.50
Previous Day 246.92247.00

Found Insights useful?

Marksans Pharma Share Price Returns

1 Day	1.18%
1 Month	22.9%
3 Months	44.45%
1 Year	-5.21%
3 Years	179.92%
5 Years	198.48%

Marksans Pharma Share Recommendations

Mean recosCurrent

STRONG BUY

2 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	1	1	1	1
Buy	1	1	1	1
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	2	2	2	2

Recent Recos

Target₹124.25
OrganizationHDFC Securities
BUY

Target₹83.6
OrganizationHDFC Securities
BUY

Target₹66.6
OrganizationHDFC Securities
BUY

View all Stock Recommendations

News & Analysis

View all Marksans Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	774.57	741.98	625.63	724.98	709.70
Total Income Growth (%)	4.39	18.60	-13.70	2.15	8.69
Total Expenses	618.01	602.83	542.97	605.45	563.77
Total Expenses Growth (%)	2.52	11.03	-10.32	7.39	7.23
EBIT	156.56	139.15	82.66	119.53	145.93
EBIT Growth (%)	12.51	68.33	-30.84	-18.09	14.69
Profit after Tax (PAT)	113.20	98.25	58.32	90.55	104.56
PAT Growth (%)	15.22	68.48	-35.59	-13.41	8.11
EBIT Margin (%)	20.21	18.75	13.21	16.49	20.56
Net Profit Margin (%)	14.61	13.24	9.32	12.49	14.73
Basic EPS (₹)	2.50	2.17	1.29	2.00	2.31

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	355.59	378.63	321.74	307.17	334.37
Total Income Growth (%)	-6.09	17.68	4.74	-8.13	-1.65
Total Expenses	273.11	256.82	257.87	256.96	259.35
Total Expenses Growth (%)	6.34	-0.41	0.35	-0.92	-1.53
EBIT	82.47	121.81	63.88	50.21	75.03
EBIT Growth (%)	-32.29	90.69	27.21	-33.07	-2.07
Profit after Tax (PAT)	60.91	99.81	48.06	37.59	55.46
PAT Growth (%)	-38.97	107.69	27.84	-32.22	-12.25
EBIT Margin (%)	23.19	32.17	19.85	16.35	22.44
Net Profit Margin (%)	17.13	26.36	14.94	12.24	16.59
Basic EPS (₹)	1.34	2.20	1.06	0.83	1.22

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	2,693.22	2,227.83	1,911.45	1,532.69	1,382.88
Total Revenue Growth (%)	20.89	16.55	24.71	10.83	21.89
Total Expenses	2,189.25	1,804.30	1,573.80	1,285.18	1,080.71
Total Expenses Growth (%)	21.34	14.65	22.46	18.92	10.57
Profit after Tax (PAT)	380.58	313.70	266.31	186.81	238.54
PAT Growth (%)	21.32	17.80	42.55	-21.68	97.54
Operating Profit Margin (%)	19.65	19.96	18.72	17.16	22.53
Net Profit Margin (%)	14.51	14.40	14.37	12.53	17.33
Basic EPS (₹)	8.40	6.92	6.41	4.51	5.76

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	1,244.21	915.35	715.69	700.54	630.70
Total Revenue Growth (%)	35.93	27.90	2.16	11.07	45.46
Total Expenses	1,000.95	743.45	583.65	566.03	506.37
Total Expenses Growth (%)	34.63	27.38	3.11	11.78	32.95
Profit after Tax (PAT)	188.27	133.76	102.87	103.99	98.38
PAT Growth (%)	40.76	30.03	-1.08	5.70	159.56
Operating Profit Margin (%)	20.81	20.26	20.70	21.00	21.62
Net Profit Margin (%)	16.03	15.67	15.69	15.79	16.40
Basic EPS (₹)	4.15	2.95	2.48	2.54	2.40

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 14.26% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	3,239.63	2,680.95	2,190.39	1,640.10	1,228.25
Total Assets Growth (%)	20.84	22.40	33.55	33.53	36.07
Total Liabilities	750.25	595.05	425.32	417.13	322.90
Total Liabilities Growth (%)	26.08	39.91	1.96	29.18	27.35
Total Equity	2,489.38	2,085.91	1,765.07	1,222.97	905.35
Total Equity Growth (%)	19.34	18.18	44.33	35.08	39.47
Current Ratio (x)	4.62	4.78	4.91	3.37	3.02
Total Debt to Equity (x)	0.01	0.01	0.02	0.03	0.02
Contingent Liabilities	34.15	45.87	9.31	17.02	19.78

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	1,755.30	1,516.04	1,344.86	965.61	718.55
Total Assets Growth (%)	15.78	12.73	39.28	34.38	19.80
Total Liabilities	371.82	293.33	233.54	180.94	118.84
Total Liabilities Growth (%)	26.76	25.60	29.07	52.26	26.22
Total Equity	1,383.49	1,222.71	1,111.32	784.67	599.72
Total Equity Growth (%)	13.15	10.02	41.63	30.84	18.61
Current Ratio (x)	3.13	3.48	4.22	3.54	3.68
Total Debt to Equity (x)	0.00	0.00	0.00	0.01	0.00
Contingent Liabilities	23.89	22.06	9.31	114.36	115.10

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	206.66	230.41	237.41	99.26	-
Net Cash used in Investing Activities	-49.01	-140.84	-259.21	-41.69	-
Net Cash flow from Financing Activities	-65.15	-68.73	197.83	79.51	-
Net Cash Flow	92.51	20.84	176.03	137.08	-
Closing Cash & Cash Equivalent	495.79	403.28	382.44	349.27	-
Closing Cash & Cash Equivalent Growth (%)	22.94	5.45	9.50	275.07	0.00
Total Debt/ CFO (x)	0.11	0.13	0.18	0.42	-

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	31.02	34.05	51.73	50.97	107.07
Net Cash used in Investing Activities	17.24	-114.22	-194.62	-8.40	8.82
Net Cash flow from Financing Activities	-29.92	-26.22	210.02	75.86	-13.53
Net Cash Flow	18.34	-106.38	67.12	118.44	102.36
Closing Cash & Cash Equivalent	60.27	41.93	148.31	224.05	105.71
Closing Cash & Cash Equivalent Growth (%)	43.74	-71.73	-33.80	111.94	3,749.92
Total Debt/ CFO (x)	0.00	0.00	0.00	0.10	0.00

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 248.27 cr for investing activities which is an YoY increase of 406.57%. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	15.42	15.19	15.25	15.53	26.90
Return on Capital Employed (%)	18.66	18.97	18.75	19.93	33.35
Return on Assets (%)	11.74	11.70	12.15	11.39	19.42
Interest Coverage Ratio (x)	51.37	45.43	43.67	35.61	38.83
Asset Turnover Ratio (x)	0.89	0.89	0.97	1.04	112.04
Price to Earnings (x)	26.53	21.93	12.00	9.99	8.58
Price to Book (x)	4.08	3.33	1.83	1.55	2.31
EV/EBITDA (x)	15.72	12.27	6.37	5.24	5.40
EBITDA Margin (%)	22.83	23.37	21.52	20.17	25.16

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	13.60	10.93	9.25	13.25	16.40
Return on Capital Employed (%)	17.33	13.90	12.02	17.30	20.79
Return on Assets (%)	10.72	8.82	7.64	10.76	13.69
Interest Coverage Ratio (x)	233.29	204.46	42.18	41.10	24.26
Asset Turnover Ratio (x)	0.72	0.60	0.57	0.78	83.43
Price to Earnings (x)	53.76	51.55	31.06	17.95	20.79
Price to Book (x)	7.28	5.62	2.87	2.38	3.41
EV/EBITDA (x)	35.81	32.45	18.07	10.55	13.38
EBITDA Margin (%)	23.32	23.67	23.25	23.69	24.16

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
34%
Positive Movement
since 1st Jan 2005
on basis
56%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Marksans Pharma	27.09	3.71	13.82	17.53	10.82	16.46	19.81	14.23	9.22	5.17	0.01	0.06
Sequent Scientific	91.02	3.50	6.08	12.55	3.83	33.99	13.52	6.56	4.09	2.38	0.15	1.35
Shilpa Medicare	43.31	4.07	9.39	11.36	6.56	13.06	21.10	14.69	12.44	1.31	0.25	1.92
Akums Drugs & Pharmaceuticals Ltd.	37.57	2.88	7.70	11.40	4.68	6.57	11.38	5.88	16.67	3.25	0.02	0.06
Strides Shasun	16.39	2.90	17.89	21.66	8.02	9.75	17.98	11.81	60.34	1.25	0.54	2.38
Add More

Annual Ratios (%)

Choose from Peers

Supriya Lifescience
Suven Life Sci
Sun Pharma Adv Res.
FDC Ltd
Aarti Pharmalabs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 19,88,22,009 43.87 % 0.00
Pledge 0 0.00 % 0.00
FII 7,59,69,458 16.75 % 8.62
DII 2,97,89,099 6.57 % 0.66
MF 2,11,23,491 4.66 % 0.25
Others 14,85,83,180 32.81 % -9.28
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 43.87 43.87 43.87 43.87
Pledge 0.00 0.00 0.00 0.00
FII 16.75 8.13 16.92 19.89
DII 6.57 5.91 5.28 5.50
Mutual Funds 4.66 4.41 3.92 3.55
Others 32.81 42.09 33.93 30.74

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Bandhan Small Cap Direct-G
Equity: Small Cap
5
- 65.09
  Amount Invested (in Cr.)
- 0.26%
  % of AUM
- 5.69
  % Change (MoM basis)
UTI Small Cap Direct-G
Equity: Small Cap
2
- 59.20
  Amount Invested (in Cr.)
- 1.21492176%
  % of AUM
- 0.00
  % Change (MoM basis)
Kotak Special Opportunities Direct-G
Equity: Thematic
- 48.52
  Amount Invested (in Cr.)
- 3.39544283%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Marksans Pharma Top Searches

Corporate Actions

Recent
Final
90%
May 26, 2026
Board Meeting
Audited Results & Final Dividend
May 12, 2026
Board Meeting
Quarterly Results
Jan 09, 2026

Announced on	Meeting on
May 12, 2026	May 26, 2026
Audited Results & Final Dividend
Jan 09, 2026	Feb 05, 2026
Quarterly Results
Oct 23, 2025	Nov 13, 2025
Quarterly Results
Jul 24, 2025	Aug 12, 2025
Quarterly Results
May 08, 2025	May 19, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 19, 2025 Aug 01, 2025 80%
May 30, 2024 Sep 17, 2024 60%
May 25, 2023 Jun 07, 2023 50%
May 30, 2022 Aug 19, 2022 25%
May 26, 2026 - 90%
Bonus
No Data Available
Splits
Announced on Ex-Date
Jan 25, 2008 Mar 11, 2008
Split: Old FV10.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jul 11, 2025 Aug 08, 2025
-
Aug 19, 2024 Sep 24, 2024
-
Aug 01, 2023 Aug 28, 2023
-
Aug 11, 2021 Sep 23, 2021
-
Jun 16, 2021 Jul 09, 2021
-

About Marksans Pharma

Marksans Pharma Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 11,189.52 Crore) operating in Pharmaceuticals sector.

Marksans Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives and Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 891.29 Crore, up 15.07 % from last quarter Total Income of Rs 774.57 Crore and up 22.94 % from last year same quarter Total Income of Rs 724.98 Crore. Company has reported net profit after tax of Rs 149.03 Crore in latest quarter.

The company’s top management includes Mr.Mark Saldanha, Mrs.Sandra Saldanha, Mr.Varddhman V Jain, Dr.Sunny Sharma, Mr.Abhinna Sundar Mohanty, Mr.Digant Mahesh Parikh, Mrs.Shailaja Vardhan, Mr.Srinivas Mishra, Mr.Jitendra Sharma, Mr.Anjani Kumar, Mr.Harshavardhan Panigrahi. Company has MSKA & Associates as its auditors. As on 31-03-2026, the company has a total of 45.32 Crore shares outstanding.

Marksans Pharma Share Price Today is Rs. 249.83. On previous day, the Marksans Pharma Share Price (NSE) closed at Rs. 252.75, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 43.87% of the stake in Marksans Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Marksans Pharma stocks was 16.76% as compared to 8.13% in Dec 2025 with increase of 8.63%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 6.57% as compared to 5.91% in Dec 2025 with increase of 0.66%. Out of the total DII holdings in Marksans Pharma shares 4.66% was held by mutual funds. The rest including public held is 32.8%. Marksans Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Marksans Pharma Dividend: Ever since 1992, Marksans Pharma dividends has been paid out around 20 times. As on 11 Jun, 2026, 03:54 PM IST, The overall dividend yield for Marksans Pharma stands at 0.36%. The last dividend paid was on August 1, 2025 (Rs. 0.8). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 9.22.

Marksans Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 891.29 Cr. of sales and 15.07% of quarterly net profit, there have been multiple ups and downs in the Marksans Pharma stock prices in the past few weeks. For example, Marksans Pharma stock price on 3rd of June 2026 was around Rs. 242.37. Marksans Pharma share price now stands at an average of Rs. 249.83. Judging by last week's performance, stock is in up trend.

Marksans Pharma has a median target price of Rs. 254.0 in 12 months by 2 analysts. They have provided a high estimate of Rs. 298.0 and low estimate of Rs. 210.0 for Marksans Pharma share.

Historical Prices and Performance:
Marksans Pharma, incorporated in 1992 is a Mid Cap company (with a market cap of Rs. 11189.52) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Marksans Pharma stock was 13.82%, 15.42%, 15.19%, 15.25% and 15.53% respectively.
The Marksans Pharma share gave a 3 year return of 176.66% as compared to Nifty 50 which gave a return of 25.06%.
Marksans Pharma announced 80.0% final dividend on August 1, 2025.

Key Metrics:
PE Ratio of Marksans Pharma is 27.41
Prices/Sales Ratio of Marksans Pharma is 2.41
Price/Book Ratio of Marksans Pharma is 3.75

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Marksans Pharma, major competitors and peers include Sequent Scientific, Shilpa Medicare, Akums Drugs & Pharmaceuticals Ltd. and Strides Shasun . As of Dec 2025, the dividend yield of Marksans Pharma stands at 0.36% while Sequent Scientific, Shilpa Medicare, Akums Drugs & Pharmaceuticals Ltd. and Strides Shasun stand at 0.0%, 0.11%, 0.17% and 0.51% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 27.41 and 3.75 respectively.

Leadership of Marksans Pharma :
Harshavardhan Panigrahi is Co. Secretary & Compl. Officer
Jitendra Sharma is Group Chief Financial Officer
Anjani Kumar is Chief Operating Officer - US Operations
Mark Saldanha is Chairman & Managing Director
Sandra Saldanha is Whole Time Director
Varddhman V Jain is Whole Time Director
Sunny Sharma is Non Executive Director
Srinivas Mishra is Independent Director
Digant Mahesh Parikh is Independent Director
Abhinna Sundar Mohanty is Independent Director
Shailaja Vardhan is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, Nifty Smallcap 500, Nifty Microcap 250

Address

11th Floor, Grandeur,Veera Desai Extension Road,Oshiwara, Andheri (West),Mumbai, Maharashtra - 400053

Contact

companysecretary@marksanspharma.com

http://www.marksanspharma.com

Executive Leadership

MS

Mark Saldanha

Chairman & Managing Director

SS

Sandra Saldanha

Whole Time Director

VV

Varddhman V Jain

Whole Time Director

SS

Sunny Sharma

Non Executive Director

Show More

Auditors

MSKA & Associates

Bhuta Shah & Co. LLP

FAQs about Marksans Pharma share

1. What's Marksans Pharma share price today and what are Marksans Pharma share returns ?
Marksans Pharma share price is Rs 249.83 as on 11 Jun, 2026, 03:54 PM IST. Marksans Pharma share price is up by 1.18% based on previous share price of Rs 252.75. Marksans Pharma share price trend:
- Last 12 Months: Marksans Pharma share price moved down 5.21%
- Last 3 Years: Marksans Pharma Share price moved up by 179.92%
2. What is 52 week high/low of Marksans Pharma share price?
52 Week high of Marksans Pharma share is Rs 270.70 while 52 week low is Rs 155.00
3. What is the PE & PB ratio of Marksans Pharma?
The PE ratio of Marksans Pharma stands at 26.78, while the PB ratio is 3.67.
4. What are the returns for Marksans Pharma share?
Return Performance of Marksans Pharma Shares:
- 1 Week: Marksans Pharma share price moved up by 4.47%
5. What's the market capitalization of Marksans Pharma?
Within the Pharmaceuticals sector, Marksans Pharma stock has a market cap rank of 42. Marksans Pharma has a market cap of Rs 11,336.34 Cr.

Top Gainers

As on 03:59 PM | 11 Jun 2026

Aegis Logistics

925.90

124.90 (15.60%)

111.45

8.52 (8.28%)

DOMS Industries

2,255.40

136.81 (6.46%)

Blue Jet Healthcare

498.45

28.70 (6.11%)

1,923.80

90.80 (4.96%)

Top Losers

As on 03:59 PM | 11 Jun 2026

Balkrishna Ind.

1,974.00

-109.20 (-5.25%)

1,133.10

-60.31 (-5.06%)

155.70

-7.93 (-4.85%)

166.91

-8.00 (-4.57%)

Adani Transmission

1,466.70

-68.90 (-4.49%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.